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Abstract
Objectives To test the accuracy of clinical pre-test probability (PTP) for prediction of obstructive coronary artery disease (CAD)
in a pan-European setting.
Methods Patients with suspected CAD and stable chest pain who were clinically referred for invasive coronary angiography
(ICA) or computed tomography (CT) were included by clinical sites participating in the pilot study of the European multi-centre
DISCHARGE trial. PTP of CAD was determined using the Diamond-Forrester (D+F) prediction model initially introduced in
1979 and the updated D+F model from 2011. Obstructive coronary artery disease (CAD) was defined by one at least 50%
diameter coronary stenosis by both CT and ICA.
Results In total, 1440 patients (654 female, 786 male) were included at 25 clinical sites fromMay 2014 until July 2017. Of these
patients, 725 underwent CT, while 715 underwent ICA. Both prediction models overestimated the prevalence of obstructive
CAD (31.7%, 456 of 1440 patients, PTP: initial D+F 58.9% (28.1–90.6%), updated D+F 47.3% (34.2–59.9%), both p < 0.001),
but overestimation of disease prevalence was higher for the initial D+F (p < 0.001). The discriminative ability was higher for the
updated D+F 2011 (AUC of 0.73 95% confidence interval [CI] 0.70–0.76 versus AUC of 0.70 CI 0.67–0.73 for the initial D+F;
p < 0.001; odds ratio (or) 1.55 CI 1.29–1.86, net reclassification index 0.11 CI 0.05–0.16, p < 0.001).
Conclusions Clinical PTP calculation using the initial and updated D+F prediction models relevantly overestimates the actual
prevalence of obstructive CAD in patients with stable chest pain clinically referred for ICA and CT suggesting that further
refinements to improve clinical decision-making are needed.
Trial registration https://www.clinicaltrials.gov/ct2/show/NCT02400229
Key Points
• Clinical pre-test probability calculation using the initial and updated D+F model overestimates the prevalence of obstructive
CAD identified by ICA and CT.
• Overestimation of disease prevalence is higher for the initial D+F compared with the updated D+F.
• Diagnostic accuracy of PTP assessment varies strongly between different clinical sites throughout Europe.
Keywords Coronary artery disease . Computed tomography angiography . Probability of disease . Prevalence
Abbreviations
AUC The area under the receiver-operating-characteristic
curve
CAD Coronary artery disease
CT Computed tomography
D+F Diamond-Forrester
ICA Invasive coronary angiography
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Introduction
In clinical routine, coronary artery disease (CAD) can be di-
agnosed by using invasive and non-invasive diagnostic tests.
Choosing the appropriate and most beneficial diagnostic test
for each patient is highly important, [1] since invasive and
non-invasive tests have different advantages and disadvan-
tages. Invasive coronary angiography (ICA) enables invasive
therapeutic measures in the same session, but is associated
with a small risk of procedural complications [2, 3]. These
risks can be avoided in clinical practice by using non-
invasive tests instead [4]. Coronary computed tomography
(CT) angiography is a safe non-invasive diagnostic test [5]
with a very high negative predictive value, making it especial-
ly valuable for ruling out obstructive CAD [6–8]. The calcu-
lation of pre-test probability (PTP) of disease can facilitate
selecting patients with stable angina pectoris for the most ben-
eficial diagnostic procedure [9]. The current European
Guidelines recommend the selection of the appropriate diag-
nostic test according to the individual patient’s CAD proba-
bility [10, 11]. Thus, the correct assessment of the likelihood
of CAD is important to select patients for the diagnostic pro-
cedure with the highest expected clinical benefit [12].
Multiple PTP calculators exist and have been established in
clinical practice. The Diamond-Forrester (D+F) PTP calcula-
tion model, which is recommended by the current European
guidelines for patients with stable chest pain, was introduced
as early as 1979 (initial D+F) and is based on three clinical
parameters that have to be assessed in patients (the patient’s
age, the type of angina presentation, and the patient’s gender)
[13]. Studies have shown that the original D+F model
overestimated the prevalence of CAD [14, 15]. The original
D+F was statistically updated by Genders et al in 2011 to
improve the prediction of obstructive CAD especially in
women and patients with atypical angina presentation (up-
dated D+F 2011) being clinically referred to ICA [16]. The
purpose of this study was to analyse the accuracy of PTP
calculation of CAD using the original and updated D+F pre-
diction models in patients with stable chest pain with a clinical
referral for either CT or ICA in a multi-centre pan-European
setting [17].
Materials and methods
Study design and patient recruitment
This study was performed as part of the pilot study of the
European multi-Diagnostic Imaging Strategies for Patients
With Stable Chest Pain and Intermediate Risk of Coronary
Artery Disease’ (DISCHARGE) trial (www.dischargetrial.
eu; FP7 2007-2013, EC-GA 603266; trial registration
https://www.clinicaltrials.gov/ct2/show/NCT02400229) [18].
The DISCHARGE trial compares the effectiveness of
invasive versus non-invasive coronary angiography. Patients
were prospectively included by 25 clinical sites across Europe
from 16 European countries.
The DISCHARGE pilot study was conducted in patients
clinically referred for either CT or ICA. Both examinations
were performed at the Department of Radiology/Cardiology at
each of the 25 clinical sites. The decision for either diagnostic
test was made in an outpatient setting, and the patients were
then clinically referred to elective CT or ICA. Before alloca-
tion to the subsequent clinical test, the clinical parameters for
PTP calculation were assessed in all patients. The complete
recruitment period was about 3 years, extending from April
2014 to July 2017. The mean recruitment period per clinical
site was 8 months (8.1 ± 4.8 months), ranging from 1 to 17
months.
Inclusion criteria
Inclusion and exclusion criteria were relatively broad. Patients
were eligible for inclusion into the non-randomised
DISCHARGE pilot study if they had a routinely scheduled
clinical examination for suspected CAD and stable chest
discomfort/chest pain and were at least 30 years of age.
Patients with known CAD including a history of prior myo-
cardial infarction or revascularization were not included.
Patients were excluded from the study if they were not in sinus
rhythm, were pregnant, or required haemodialysis.
Study outcomes
The purpose of the pilot study was to acquire information on
the routine clinical practice of CTA and ICA at different clin-
ical sites. In this paper, we investigate the accuracy of PTP
calculation of obstructive CAD using the Diamond-Forrester
(D+F) prediction models in patients clinically referred to CT
or ICA. Each of the 25 clinical sites planned to include at least
60 patients routinely scheduled for the examinations (30 CTA
and 30 ICA).
Ethics
The ethics approval for the main DISCHARGE trial (EA1/
294/13) included the pilot study. Depending on local site re-
quirements for data acquisition, written and/or oral informed
consent was obtained from all patients participating in the
DISCHARGE pilot study. The study participants did not un-
dergo any follow-up examinations or investigational proce-
dures. The DISCHARGE project is funded by the EU-FP7
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Framework Programme (FP7 2007-2013, EC-GA 603266,
EC-GA 603266) but the clinical sites did not receive any
funding for the pilot study which was an own contribution
by all. Only research staff at the coordinator site received
funding for coordinating the pilot study.
Study conduct
The ICA and CT examinations had to be performed according
to local standards. Vendor-specific CT protocols and a 10-step
guide for CT and ICA were finalised by the DISCHARGE
consortium and distributed to all involved staff members at all
clinical sites. In addition, we performed two cardiac CT work-
shops in Berlin for the physicians involved in the examina-
tions at all clinical sites to create a comparable basis of CT
reading abilities for all participating centres [19].
Assessment of pre-test probabilities
Patients were included independently of their estimated or cal-
culated disease probability. PTP of all included patients were
assessed by comparing the initial D+F model introduced in
1979 and the updated D+F model from 2011 [13, 16]. Both
models of pre-test calculation of CAD probability include only
three clinical parameters that had to be assessed in all patients:
the patient’s age, the type of angina presentation, and the pa-
tient’s gender (Fig. 1) [20]. The typicality of angina presenta-
tion was based on the presence of the following three criteria:
retrosternal localisation of pain, precipitation by exertion, and
prompt relief by rest or after nitroglycerin. [20] Dependent on
how many criteria were fulfilled patients were allocated to one
of the following categories: typical angina (all 3 criteria pres-
ent), atypical angina (2 of 3 criteria), non-anginal chest discom-
fort (1 of 3 criteria) or other chest discomfort (no criteria ful-
filled). PTP for all patients at all sites was calculated by the
coordinating site based on the information provided in the CRF.
Assessment of obstructive CAD
Obstructive CAD was defined by ICA and CT as the pres-
ence of at least one 50% coronary artery diameter stenosis
on a per-patient level. As CT has a high sensitivity/
specificity for the detection of significant CAD, we used
CT results equally as ICA results in this study [6]. If ICA
was performed after clinically indicated CT, the ICA result
was selected for the final analysis of the accuracy of PTP,
since ICA is the reference standard for the diagnosis of
CAD. All examinations were evaluated locally at each
clinical site by qualified and trained readers for CT and
cardiologists for ICA according to their local standard of
care, e.g. by using quantitative coronary analysis.
Statistical analysis
Values are given as arithmetic mean (standard deviation), as
median (interquartile range; IQR), or as number of patients
(percentages). We performed the statistical analysis by
using SPSS version 20 and R 3.4.4 [21]. A p value of
≤ 0.05 was defined to indicate statistical significance. The
dependent t test for paired samples was used for the com-
parison of continuous variables. To compare pared dichot-
omous variables, we performed McNemar’s test. We used
the area under the receiver-operating-characteristic curve
(AUC) to compare the discriminative power of the two
pre-test prediction models. To compare the two models in
terms of their diagnostic accuracy, we performed a logistic
regression analysis with the outcome (CAD or no CAD) as a
dependent variable and the respective PTP and the method
of computation as a predictor. In order to take care of the
variability between sites, we applied a random intercept for
site and correlation between observations. In addition, we
performed a net reclassification analysis using 50% as a
cutoff value for the PTP.
Fig. 1 Three clinical parameters for pre-test probability estimation
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Results
Study population
It was planned to include 1523 patients (see flowchart in
Fig. 2 for further details). Sixty of these patients were
retrospectively excluded. The most frequent reason was
a lack of adherence to the inclusion and exclusion criteria.
Thus, 1463 eligible patients were included in the study
and underwent CT or ICA according to clinical referral.
Nevertheless, 23 patients had non-diagnostic examina-
tions and were excluded. For the final analysis, 1440 pa-
tients were included (654 female and 786 male patients,
45% and 55%, respectively). In this final population, 725
patients underwent CT (358 female, 367 male) and 715
underwent ICA (296 female, 419 male).
Patient characteristics
The number of patients with typical chest pain was higher in
the ICA group than in the CT group with 53% (378 of 715)
versus 35% (253 of 725; Table 1). There were more patients
with atypical angina/non-anginal chest pain or other chest
discomfort in the CT group (65%) compared with those in
the ICA group (47%). The mean age of patients was 64 years
in the ICA group (63.8 ± 9.7 years; Table 1) and 59 years in
the CT group (58.7 ± 11.3 years) with an overall range of 30–
86 years. The male-to-female ratio was slightly higher in the
ICA group with 59% male patients (419 male and 296 female
patients) than in the CT group with 51% male patients (367
male and 358 female patients).
Examination results and accuracy of pre-test proba-
bility prediction
The overall prevalence of obstructive CAD was 31.7%
(456 of 1441 patients; Figure 3). In detail, the prevalence
was higher in the ICA group (45.1%; 322 of 715 patients)
compared with the CT group (18.5%; 134 of 725 patients;
p < 0.001), and the overall prevalence ranged between
15.3% and 49.2% among the 25 c l in ica l s i t es
(Supplementary material, Online Figure 1). In the ICA
group, the prevalence at the individual clinical sites
ranged between 23.3% and 76.7%, and between 3.4%
and 34.5% in the CT group.
The prevalence of obstructive CAD identified by ICA
and CT (31.7%, 456 of 1440 patients) was overestimated
by both prediction models (PTP: initial D+F 58.9% (28.1–
90.6%) and updated D+F 47.3% (34.2–59.9%), both
p < 0.001; Fig. 3). Comparison of both prediction models
showed overestimation of CAD to be slightly less for the
updated D+F compared with the initial version (p < 0.001).
The PTP calculated with the initial D+F version was 51% in
the CT group (median 54.4% (18.6–79.4%)) versus 65% in
Fig. 2 Flowchart of the pilot
study. A total of 1463 patients
were eligible for study inclusion.
For the final analysis, we included
1440 patients (with 654 female
and 786 male patients)
Eur Radiol
the ICA group (median 69.7% (32.4–92%)). In both groups,
the PTP of CAD was significantly lower when calculated
with the updated D+F version: 43% in the CT group (medi-
an 41.4% (29.8–53.2%)) and 53% in the ICA group (median
51.8% (40.6–65.4%)). Thus, both pre-test calculators
overestimated the actual prevalence of obstructive CAD of
45% in the ICA group and 19% in the CT group (p < 0.001).
The overestimation was higher for the initial D+F calcula-
tion compared with the updated D+F version in both the CT
and the ICA group (p < 0.001) and was higher in the CT
group compared with that in the ICA group (p < 0.001) for
both prediction models.
Discriminative ability and NET reclassification analysis
The discriminative ability was stronger for the updated D+F
2011 with an area under the receiver operating curve of 0.73
(AUC; 95% confidence interval [CI] 0.70–0.76; Fig. 4) com-
pared with an AUC of 0.70 (CI 0.67–0.73) for the initial D+F
prediction model (p < 0.001). The discriminative ability dif-
fered between the 25 clinical sites (Supplementary material,
Online Figure 2). The logistic regression analysis with random
intercept for the site showed a significant effect of the method
with a coefficient equal to 0.44. This corresponds to an odds
ratio of 1.55 (95% CI 1.29–1.86; Table 2). Thus, this result is
Fig. 3 Pre-test probability and coronary artery disease (CAD) prevalence.
A total of 725 patients underwent CT, and 715 underwent ICA. The
average prevalence of obstructive CAD in the entire population was
32% with a higher prevalence in the ICA group (45%) versus the CT
group (19%). The actual disease probability was relevantly overestimated
by both prediction models with a higher overestimation of disease
prevalence for the initial version compared with the updated D+F (p <
0.001). This overestimation again was higher in the CT group compared
with that in the ICA group (p < 0.001)
Table 1 Distribution of clinical
parameters in the ICA and CT
group
ICA group (N = 715) CT group (N = 725)
Symptoms Typical angina pectoris 378 (52.9%) 253 (34.9%) *
Atypical angina pectoris 166 (23.2%) 247 (34.1%) *
Non-anginal chest discomfort 142 (19.9%) 194 (26.8%) *
Other chest discomfort 29 (4.1%) 31 (4.3%)
Gender Female 296 (41.4%) 358 (49.3%)
Male 419 (58.6%) 367 (50.6%)
Age Median (IQR), year 64 (57–72) 58 (51–67)
The number of patients with typical chest pain was higher in the ICA group than in the CT group (53% versus
35%). More patients in the CT group presented with atypical angina or non-anginal chest pain than in the ICA
group (61% versus 43%). The mean age of patients was higher in the ICA group than in the CT group (64 versus
59 years). The male-to-female ratio was slightly higher in the ICA group compared with that in the CT group.
*Statistical significance
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in favour of the updated D+F model. There is also substantial
variability between sites measured by the variance of the ran-
dom intercepts with a value of 0.14.
As a result of the NET reclassification analysis, there is
an improvement due to the updated D+F model (NRI cat-
egorical 0.11 95% CI (0.05–0.16); p < 0.001; Table 3).
Thus, using a cutoff value of 50% PTP for CAD, the up-
dated D+F model particularly reclassifies patients without
CAD but with a PTP of ≥ 50% to a PTP < 50% compared
with the initial D+F model.
Discussion
The results of this multi-centre European study show the
following:
1. The PTP calculated by the D+F model (initial and statis-
tically updated version) relevantly overestimates the actu-
al prevalence of CAD in patients clinically referred for
ICA and CT with stable chest pain.
2. The updated D+F performs slightly better than the initial
D+F.
3. Overestimation is higher in patients clinically referred to
CT than in those clinically referred to ICA.
4. There is tremendous variability in the diagnostic accuracy
of PTP assessment between different clinical sites which
were trained in the basic concept of PTP assessment and
evaluation of chest pain type.
Interpretation of the results in the clinical context
In this multi-centre clinical trial, we compared the CAD PTP
estimation of the initial D+F with the updated D+F in a non-
selective pragmatic cohort of both patients referred on clinical
grounds to CTA as well as ICA. Our trial shows that the statis-
tically updated D+F has a slightly higher discriminative ability
Table 2 Logistic regression
analysis with random effects Random effects
Groups name Variance Standard deviation
Clinical site (intercept) 0.1371 0.3703
Number of observations, 2880;
groups: site, 25
Fixed effects
Estimate Standard error Z value Pr (>|z|)
(Intercept) − 2.734 0.16884 − 16.192 < 2e–16***
Pre-test probability 3.04813 0.19998 15.243 < 2e–16***
Method (original D+F or
updated D+F 2011)
0.43833* 0.09312 4.707 2.51e–06***
Correlation of fixed effects
(Intercept) Pre-test probability
Pre-test probability − 0.818
Method (original D+F
or updated D+F 2011)
− 0.566 0.392
We performed a logistic regression analysis with the outcome (prevalence; CAD or noCAD) as dependent and the
respective pre-test probability and the method of computation as predictors using the stacked data set (method
original D+F versus updated D+F 2011). In order to take care of the variability between sites, we applied a random
intercept for site. There is a significant effect of the method with a coefficient equal to 0.44, corresponding to an
odds ratio of 1.55 (95%CI 1.29, 1.86). Significance codes: 0 = ‘***’, 0.001 = ‘**’, 0.01 = ‘*’, 0.05 = ‘.’ 0.1 = ‘ ’ 1;
*Statistical significance
Fig. 4 Comparison of the discriminative power of pre-test probability
prediction models. The discriminative ability was higher for the updated
D+F 2011 compared with the initial D+F prediction model. The AUC,
which is a parameter of the discriminative ability, was 0.73 for the
updated D+F (AUC; 95% confidence [CI] interval 0.70–0.76). The
initial D+F had an AUC of 0.70 (95% CI 0.67–0.73; p < 0.001)
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and therefore tends to estimate the CAD probability more ac-
curately than the initial D+F [13, 16]. For patients routinely
scheduled for ICA, the clinical estimation of PTP was more
exact than for patients referred for CTA. Possibly, the reason
is not primarily the diagnostic test itself for which the patients
are scheduled, but the clinical presentation which resulted in the
decision to refer the patients for either diagnostic test [22]. In
our patient population, the prevalence was higher for the pa-
tients scheduled for ICA than for the CT patients. In this non-
randomised study setting, this is logical from the clinical point
of view, since ICA offers the possibility of subsequent treat-
ment with angioplasty and coronary stenting.
Our results show variable prevalence of obstructive CAD
in patients routinely scheduled for ICA and CTA for the 25
clinical sites included in our analysis. Since the prevalence of
disease influences the accuracy of the applied clinical tests, it
is highly important to know the local disease prevalence [10].
As our study sites are spread across Europe, multiple factors
affect the local disease prevalence and discriminative ability.
Overestimation of PTP of CAD will lead subsequently to in-
creased downstream diagnostic testing which increases the
possibility of adverse events and costs for the health care
system. As recent studies have shown [23], the prevalence
of obstructive CAD is relatively low in patients electively
referred to ICA/CT to evaluate stable chest pain.
Comparison with other studies
This study includes a large-scale prospective European cohort
with both CTA and ICA being the combined gold standard in
a non-specified patient cohort. Recent scientific data on the
clinical application of PTP calculation in patients with
suspected CAD are rare.
There are only few other papers that have assessed the
accuracy of the D+F model to patients referred for CTA.
They all have in common to include only patients with
low PTP being clinically assigned to CT but do not com-
pare with patients clinically referred to ICA. A study of
Wasfy et al [24] was in an American cohort including
patients being referred only for CTA based on a low
PTP. A more recent study evaluated 3 scores among pa-
tients with suspected CAD in the CTA randomised arm of
the SCOT-HEART study for the outcome of obstructive
CAD by coronary CTA [25]: the modified D+F, CAD
Consortium clinical score (CAD2), and CONFIRM risk
score (CRS). They found that the best calibrator of ob-
structive CAD was the updated D+F, which goes in line
with the results of our study. Another study has shown
PTP calculation according to D+F to overestimate PTP of
CAD in a multi-centre study setting with patients being
also only referred to CT not ICA [14]. This was shown in
our study as well. However, in our patient collective, pa-
tients were referred to both, CTA and ICA, based on clin-
ical estimation. The study population of Cheng et al was
also characterised by a relatively low prevalence of dis-
ease of 15%. The recently published study of Foldyna
et al showed overestimation of the D+F model in a large
multi-centric cohort from the PROMISE trial [26]. This is
in accordance with the results of our study. Again, in
comparison with our study, the study of Foldyna et al
only included patients being randomised to CTA.
Thus, the analysis of our European DISCHARGE cohort
provides a unique opportunity to make comparisons between
pre-test models for patients referred for both CTA and ICA in
25 European sites providing performance analysis for both
models in a non-selective pragmatic cohort.
Table 3 NET reclassification
index Updated D+F 2011 (n) % Reclassified
Outcome: no CAD (n = 984)
Pre-test probability < 50% ≥ 50%
Initial D+F < 50% 381 41 10
≥ 50% 266 296 47
Outcome: CAD (n = 456)
Pre-test probability < 50% ≥ 50%
Initial D+F < 50% 66 23 26
≥ 50% 79 288 22
Combined data
Pre-test probability < 50% ≥ 50%
Initial D+F < 50% 477 64 13
≥ 50% 345 584 37
NRI (categorical) [95% CI], 0.1059 [0.0532–0.1585]; p value, 0.00008
Net reclassification analysis using 50% as a cutoff value for the pre-test probability. As a result, it turns out that
there is an improvement due to the Genders model (NRI categorical 0.11 95% CI (0.05–0.16); p < 0.001); n
number of patients
Eur Radiol
Strengths and limitations
This multi-centre study included patients from clinical sites
across Europe. Our patient population is very robust, includ-
ing patients from 25 different clinical sites, with a high overall
patient number of more than 1000 patients, and an almost
similar male-to-female ratio in both the CT and ICA group.
This pilot study was planned to prepare the subsequent
randomised controlled trial. Therefore, patients were routinely
sent for CT and ICA examinations per clinical indication.
However, this study was not designed as a controlled
randomised trial.
In this study, we used both CT and ICA examination as the
diagnostic gold standard. This is due to the fact that various
clinical studies have proven the high diagnostic accuracy of
coronary CT angiography and its high negative predictive
value [27]. In our study population, the clinical presentation
significantly differed between the CT and ICA group. Due to
the design of the D+F model, patient gender and age are part
of the PTP calculation and these differences do not reduce the
validity of our patient collective, but reflect routine clinical
decision-making. In this study, we did not acquire detailed
information on the patients’ medical histories (e.g. diabetes,
arterial hypertension, smoking status, family history of CAD),
CT/ICA indicators of CAD (e.g. coronary calcium score, left
ventricular function, myocardial perfusion, wall motion), or
adverse events in the follow-up. Thus, we were not able to
perform a more detailed analysis to assess the differences in
the prevalence of obstructive CAD; we observed between the
different clinical sites or using other tests for estimation of pre-
test probability (e.g. SCORE or the extended D+F model). As
the current European guidelines recommend the D+F model
statistically updated by Genders et al in order to select patients
for further diagnostic tests, we decided to request only clinical
data for the fast and intuitive initial and updated D+F estima-
tion model.
Both the AUCs of the D+F models and the prevalence of
significant CAD, which reflects post-test probability, varied
strongly among the European sites participating in the study.
Conclusions
This study demonstrates that the initial and updated D+F
models relevantly overestimate the PTP of CAD compared
with its actual prevalence in patients routinely selected for
both CT and ICA. The updated D+F model was slightly more
accurate than the initial D+F version. The prevalence of ob-
structive CAD differs between clinical sites in Europe. Thus,
in order to choose the most beneficial diagnostic test for pa-
tients as recommended by the European guidelines, the over-
estimation of the actual prevalence of CAD and differences in
prevalence among European countries need to be considered.
More accurate clinical prediction tools are needed to optimize
clinical decision-making for the diagnostic management of
patients with suspected CAD.
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